Germany's BioNTech 2025 revenue beats expectations, helped by Bristol Myers Squibb collaboration

Reuters03-10
Germany's BioNTech 2025 revenue beats expectations, helped by Bristol Myers Squibb collaboration 

Overview

  • Germany-based immunotherapy firm's 2025 revenue rose, beating analyst expectations

  • Company reported a net loss of €1.14 bln for 2025

  • BioNTech co-founders to form independent mRNA innovation company by 2026; management transition by end of 2026

Outlook

  • BioNTech expects 2026 revenue between €2.0 bln and €2.3 bln

  • Company anticipates lower COVID-19 vaccine revenues in 2026

  • BioNTech plans adjusted R&D expenses of €2.2-2.5 bln for 2026

Result Drivers

  • COVID-19 VACCINE DEMAND - Quarterly revenue decline driven by reduced COVID-19 vaccine sales

  • BMS COLLABORATION - Full-year revenue increase attributed to collaboration with Bristol Myers Squibb

  • COST MANAGEMENT - R&D expenses decreased due to cost savings and cost-sharing with BMS

Company press release: ID:nGNE3g8XWh

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Revenue

Beat

EUR 2.87 bln

EUR 2.74 bln (21 Analysts)

FY EPS

-EUR 4.70

FY Net Income

-EUR 1.14 bln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Biontech SE is $140.00, about 37% above its March 9 closing price of $102.16

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment